Timing is everything: new trial aims to save lives from immune storm
NCT ID NCT07497438
First seen Apr 04, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study compares giving the drug etoposide early versus waiting when treating severe hemophagocytic lymphohistiocytosis (HLH) in intensive care. HLH is a life-threatening overreaction of the immune system that can cause organ failure. The goal is to see if early treatment reduces organ damage and improves survival in 176 adult ICU patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Intensive Care Unit - Avicenne Hospital, Assistance Publique des Hôpitaux de Paris
Bobigny, 93000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.